Revenue: The sum of all revenue fields included for a company's operating activities.
Alnylam Pharmaceuticals, Inc. (ALNY) had Revenue of $2.25B for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
|
Revenue |
$2.25B |
$-278.16M |
|
$323.37M |
|
$1.92B |
|
$2.43B |
|
$-176.88M |
|
$-200.49M |
|
$-377.38M |
|
$-377.38M |
|
$-278.16M |
|
$-278.16M |
|
$-278.16M |
|
$-278.16M |
|
$-176.88M |
|
$-120.22M |
|
127.65M |
|
127.65M |
|
$-2.18 |
|
$-2.18 |
|
| Balance Sheet Financials | |
$3.30B |
|
$502.78M |
|
$944.70M |
|
$4.24B |
|
$1.19B |
|
$1.02B |
|
$2.99B |
|
$4.17B |
|
$67.09M |
|
$67.09M |
|
$67.09M |
|
129.29M |
|
| Cash Flow Statement Financials | |
$-8.31M |
|
$-116.84M |
|
$294.16M |
|
$814.88M |
|
$968.65M |
|
$153.77M |
|
$272.08M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.78 |
|
-- |
|
-- |
|
0.94 |
|
15.27 |
|
85.62% |
|
-7.87% |
|
-7.87% |
|
-5.35% |
|
-16.79% |
|
-12.37% |
|
$-42.59M |
|
-- |
|
-- |
|
-- |
|
0.53 |
|
4.12 |
|
5.55 |
|
65.80 |
|
-414.62% |
|
-414.62% |
|
-6.56% |
|
-25.48% |
|
$0.52 |
|
$-0.33 |
|
$-0.07 |
|